iRhythm Builds Momentum Following Large Trial Of AI Approach To ECG Analysis
Results from a study of more than 91,000 ECG records collected with iRhythm’s Zio ambulatory continuous cardiac monitoring device that demonstrates the successful application of artificial intelligence to ECGs gives the 12-year-old company confidence that it will be profitable very soon.
You may also be interested in...
Health technology assessment body says that while iRhythm Technologies’ Zio XT service improves cardiac arrhythmia detection, more data must be collected to address evidence gaps about its benefit.
Who wants to go public during a once-in-a-century crisis? It seems like quite a few medtechs do.
Results of the TREAT AF trial showed low-level transcutaneous electrical stimulation of the auricular branch of the vagus nerve through the tragus of the patient’s ear reduced atrial fibrillation burden over six months.